Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.33 |
| ▸ | HTR3B | O95264 | 2/20 | 0.33 |
| ▸ | HTR3A | P46098 | 2/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP4 | P49662 | 1/20 | 0.32 |
| ▸ | CASP5 | P51878 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7573222 | 0.98 | ALDH1A1 (0.38) | HRH1USP2SMN1; SMN2TDP1ADRB1 | |
| SCHEMBL15038753 | 0.76 | NOS1 (0.35) | USP2NOS1 | |
| SCHEMBL14753506 | 0.70 | INMT (0.43) | USP2ALDH1A1LMNACHRNA4 | |
| SCHEMBL14753505 | 0.70 | INMT (0.39) | USP2ALDH1A1LMNANOS1 | |
| SCHEMBL22106040 | 0.68 | INMT (0.47) | USP2ALDH1A1LMNACHRNA4 | |
| SCHEMBL22106038 | 0.68 | INMT (0.38) | USP2 | |
| SCHEMBL13117169 | 0.67 | SIGMAR1 (0.56) | USP2ADRB1ALDH1A1ADRB2PLD1 | |
| Acetic Acid SCHEMBL25355446 | 0.67 | INMT (0.40) | — | |
| SCHEMBL22106039 | 0.67 | USP2 (0.41) | USP2ALDH1A1LMNA | |
| SCHEMBL9987736 | 0.66 | LMNA (0.30) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020147359-A1 | Intermediate compound for preparing guanidine and amidine derivatives | LUETTKE SVEN (DE) | 2002-10-10 | — | — | US | disclosed |
| US-6455700-B1 | THERAPY FOR NEUROKININ SENSITIVE DISEASE | BOEHRINGER INGELHEIM PHARMA KG. (DE) | 2002-09-24 | — | — | US | disclosed |
| US-20020133012-A1 | Process for preparing guanidine and amidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-19 | — | — | US | disclosed |
| US-6429328-B2 | REACTING AN AMIDE DERIVATIVE WITH A PIPERIDINE CONTAINING GUANIDINE GROUP TO PRODUCE THE PRODUCT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-08-06 | — | — | US | disclosed |
| US-20020010173-A1 | Processes and intermediate compounds for preparing guanidine and amidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-01-24 | — | — | US | disclosed |
| US-6277840-B1 | ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-08-21 | — | — | US | disclosed |
| EP-1086088-A2 | NOVEL NEUROKININ ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | Boehringer Ingelheim Pharma KG (DE) | 2001-03-28 | — | — | EP | disclosed |
| US-6103719-A | NEUROKININ-A- OR NEUROKININ-B TACHNKININ ANTAGONISTIC PROPERTIES; SUBSTANCE P ANTAGONISM; RESPIRATORY, GASTROINTESTINAL, NERVOUS SYSTEM, SKIN DISORDERS; | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-08-15 | — | — | US | disclosed |
| WO-1999062893-A2 | NOVEL NEUROKININ ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010173-A1 | Processes and intermediate compounds for preparing guanidine and amidine derivatives | CCKAR, NPY2R, CCKBR | HRH1 95/4885USP2 2813/4885SMN1; SMN2 2457/4885 |
| US-20020147359-A1 | Intermediate compound for preparing guanidine and amidine derivatives | NPY2R, CCKAR, NPY1R | HRH1 181/4885USP2 3271/4885SMN1; SMN2 2091/4885 |
| US-20020133012-A1 | Process for preparing guanidine and amidine derivatives | NPY2R, NPY1R, CCKAR | HRH1 113/4885USP2 3043/4885SMN1; SMN2 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.